Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

CHL1 gene acts as a tumor suppressor in human neuroblastoma.

Ognibene M, Pagnan G, Marimpietri D, Cangelosi D, Cilli M, Benedetti MC, Boldrini R, Garaventa A, Frassoni F, Eva A, Varesio L, Pistoia V, Pezzolo A.

Oncotarget. 2018 May 25;9(40):25903-25921. doi: 10.18632/oncotarget.25403. eCollection 2018 May 25.

2.

Monitoring multiple myeloma by idiotype-specific peptide binders of tumor-derived exosomes.

Iaccino E, Mimmi S, Dattilo V, Marino F, Candeloro P, Di Loria A, Marimpietri D, Pisano A, Albano F, Vecchio E, Ceglia S, Golino G, Lupia A, Fiume G, Quinto I, Scala G.

Mol Cancer. 2017 Oct 13;16(1):159. doi: 10.1186/s12943-017-0730-8.

3.

Exosomes from human mesenchymal stem cells conduct aerobic metabolism in term and preterm newborn infants.

Panfoli I, Ravera S, Podestà M, Cossu C, Santucci L, Bartolucci M, Bruschi M, Calzia D, Sabatini F, Bruschettini M, Ramenghi LA, Romantsik O, Marimpietri D, Pistoia V, Ghiggeri G, Frassoni F, Candiano G.

FASEB J. 2016 Apr;30(4):1416-24. doi: 10.1096/fj.15-279679. Epub 2015 Dec 11.

PMID:
26655706
4.

NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model.

Horenstein AL, Chillemi A, Quarona V, Zito A, Roato I, Morandi F, Marimpietri D, Bolzoni M, Toscani D, Oldham RJ, Cuccioloni M, Sasser AK, Pistoia V, Giuliani N, Malavasi F.

Cells. 2015 Sep 17;4(3):520-37. doi: 10.3390/cells4030520. Review.

5.

Failure of anti tumor-derived endothelial cell immunotherapy depends on augmentation of tumor hypoxia.

Pezzolo A, Marimpietri D, Raffaghello L, Cocco C, Pistorio A, Gambini C, Cilli M, Horenstein A, Malavasi F, Pistoia V.

Oncotarget. 2014 Nov 15;5(21):10368-81.

6.

The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma.

Ferretti E, Tripodo C, Pagnan G, Guarnotta C, Marimpietri D, Corrias MV, Ribatti D, Zupo S, Fraternali-Orcioni G, Ravetti JL, Pistoia V, Corcione A.

Leukemia. 2015 Apr;29(4):958-67. doi: 10.1038/leu.2014.291. Epub 2014 Oct 6.

PMID:
25283844
7.

Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche.

Quarona V, Ferri V, Chillemi A, Bolzoni M, Mancini C, Zaccarello G, Roato I, Morandi F, Marimpietri D, Faccani G, Martella E, Pistoia V, Giuliani N, Horenstein AL, Malavasi F.

Ann N Y Acad Sci. 2015 Jan;1335:10-22. doi: 10.1111/nyas.12485. Epub 2014 Jul 21. Review.

PMID:
25048519
8.

ATP/P2X7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment.

Bianchi G, Vuerich M, Pellegatti P, Marimpietri D, Emionite L, Marigo I, Bronte V, Di Virgilio F, Pistoia V, Raffaghello L.

Cell Death Dis. 2014 Mar 20;5:e1135. doi: 10.1038/cddis.2014.109.

9.

Proteome profiling of neuroblastoma-derived exosomes reveal the expression of proteins potentially involved in tumor progression.

Marimpietri D, Petretto A, Raffaghello L, Pezzolo A, Gagliani C, Tacchetti C, Mauri P, Melioli G, Pistoia V.

PLoS One. 2013 Sep 19;8(9):e75054. doi: 10.1371/journal.pone.0075054. eCollection 2013.

10.

Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma.

Di Paolo D, Pastorino F, Zuccari G, Caffa I, Loi M, Marimpietri D, Brignole C, Perri P, Cilli M, Nico B, Ribatti D, Pistoia V, Ponzoni M, Pagnan G.

J Control Release. 2013 Sep 28;170(3):445-51. doi: 10.1016/j.jconrel.2013.06.015. Epub 2013 Jun 19.

PMID:
23792118
11.

Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells.

Pezzolo A, Parodi F, Marimpietri D, Raffaghello L, Cocco C, Pistorio A, Mosconi M, Gambini C, Cilli M, Deaglio S, Malavasi F, Pistoia V.

Cell Res. 2011 Oct;21(10):1470-86. doi: 10.1038/cr.2011.38. Epub 2011 Mar 15.

12.

Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma.

Brignole C, Marimpietri D, Di Paolo D, Perri P, Morandi F, Pastorino F, Zorzoli A, Pagnan G, Loi M, Caffa I, Erminio G, Haupt R, Gambini C, Pistoia V, Ponzoni M.

Cancer Res. 2010 Dec 1;70(23):9816-26. doi: 10.1158/0008-5472.CAN-10-1251. Epub 2010 Oct 8.

13.

Liposome-mediated therapy of neuroblastoma.

Di Paolo D, Loi M, Pastorino F, Brignole C, Marimpietri D, Becherini P, Caffa I, Zorzoli A, Longhi R, Gagliani C, Tacchetti C, Corti A, Allen TM, Ponzoni M, Pagnan G.

Methods Enzymol. 2009;465:225-49. doi: 10.1016/S0076-6879(09)65012-6.

PMID:
19913170
14.

Recent advances in targeted anti-vasculature therapy: the neuroblastoma model.

Pastorino F, Di Paolo D, Loi M, Becherini P, Caffa I, Zorzoli A, Marimpietri D, Carosio R, Perri P, Montaldo PG, Brignole C, Pagnan G, Ribatti D, Allen TM, Ponzoni M.

Curr Drug Targets. 2009 Oct;10(10):1021-7. Review.

PMID:
19663770
15.

Anti-IL-10R antibody improves the therapeutic efficacy of targeted liposomal oligonucleotides.

Brignole C, Marimpietri D, Pastorino F, Di Paolo D, Pagnan G, Loi M, Piccardi F, Cilli M, Tradori-Cappai A, Arrigoni G, Pistoia V, Ponzoni M.

J Control Release. 2009 Sep 1;138(2):122-7. doi: 10.1016/j.jconrel.2009.05.006. Epub 2009 May 7.

PMID:
19427884
16.

The combined therapeutic effects of bortezomib and fenretinide on neuroblastoma cells involve endoplasmic reticulum stress response.

Pagnan G, Di Paolo D, Carosio R, Pastorino F, Marimpietri D, Brignole C, Pezzolo A, Loi M, Galietta LJ, Piccardi F, Cilli M, Nico B, Ribatti D, Pistoia V, Ponzoni M.

Clin Cancer Res. 2009 Feb 15;15(4):1199-209. doi: 10.1158/1078-0432.CCR-08-2477.

17.

Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.

Pastorino F, Di Paolo D, Piccardi F, Nico B, Ribatti D, Daga A, Baio G, Neumaier CE, Brignole C, Loi M, Marimpietri D, Pagnan G, Cilli M, Lepekhin EA, Garde SV, Longhi R, Corti A, Allen TM, Wu JJ, Ponzoni M.

Clin Cancer Res. 2008 Nov 15;14(22):7320-9. doi: 10.1158/1078-0432.CCR-08-0804.

18.

Drug delivery systems: application of liposomal anti-tumor agents to neuroectodermal cancer treatment.

Di Paolo D, Pastorino F, Brignole C, Marimpietri D, Loi M, Ponzoni M, Pagnan G.

Tumori. 2008 Mar-Apr;94(2):246-53.

PMID:
18564613
19.

Ligand-targeted liposomal therapies of neuroblastoma.

Pastorino F, Marimpietri D, Brignole C, Di Paolo D, Pagnan G, Daga A, Piccardi F, Cilli M, Allen TM, Ponzoni M.

Curr Med Chem. 2007;14(29):3070-8. Review.

PMID:
18220743
20.

Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis.

Marimpietri D, Brignole C, Nico B, Pastorino F, Pezzolo A, Piccardi F, Cilli M, Di Paolo D, Pagnan G, Longo L, Perri P, Ribatti D, Ponzoni M.

Clin Cancer Res. 2007 Jul 1;13(13):3977-88.

21.

Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.

Pastorino F, Brignole C, Di Paolo D, Nico B, Pezzolo A, Marimpietri D, Pagnan G, Piccardi F, Cilli M, Longhi R, Ribatti D, Corti A, Allen TM, Ponzoni M.

Cancer Res. 2006 Oct 15;66(20):10073-82.

22.

Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis.

Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, Cioni M, Piccardi F, Cilli M, Pezzolo A, Corrias MV, Pistoia V, Ribatti D, Pagnan G, Ponzoni M.

J Natl Cancer Inst. 2006 Aug 16;98(16):1142-57.

PMID:
16912267
23.

Proteomic analysis of anti-angiogenic effects by a combined treatment with vinblastine and rapamycin in an endothelial cell line.

Campostrini N, Marimpietri D, Totolo A, Mancone C, Fimia GM, Ponzoni M, Righetti PG.

Proteomics. 2006 Aug;6(15):4420-31.

PMID:
16888724
24.

Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin.

Marimpietri D, Nico B, Vacca A, Mangieri D, Catarsi P, Ponzoni M, Ribatti D.

Oncogene. 2005 Oct 13;24(45):6785-95.

PMID:
16007159
25.

Neuroblastoma targeting by c-myb-selective antisense oligonucleotides entrapped in anti-GD2 immunoliposome: immune cell-mediated anti-tumor activities.

Brignole C, Marimpietri D, Pagnan G, Di Paolo D, Zancolli M, Pistoia V, Ponzoni M, Pastorino F.

Cancer Lett. 2005 Oct 18;228(1-2):181-6. Review.

PMID:
15936140
26.

Angiogenesis in neuroblastoma.

Ribatti D, Marimpietri D, Pastorino F, Brignole C, Nico B, Vacca A, Ponzoni M.

Ann N Y Acad Sci. 2004 Dec;1028:133-42. Review.

PMID:
15650239
27.

Targeted delivery of oncogene-selective antisense oligonucleotides in neuroectodermal tumors: therapeutic implications.

Pastorino F, Brignole C, Marimpietri D, Di Paolo D, Zancolli M, Pagnan G, Ponzoni M.

Ann N Y Acad Sci. 2004 Dec;1028:90-103.

PMID:
15650235
28.

Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.

Brignole C, Pastorino F, Marimpietri D, Pagnan G, Pistorio A, Allen TM, Pistoia V, Ponzoni M.

J Natl Cancer Inst. 2004 Aug 4;96(15):1171-80.

PMID:
15292389
29.

Proteomic analysis of an orthotopic neuroblastoma xenograft animal model.

Campostrini N, Pascali J, Hamdan M, Astner H, Marimpietri D, Pastorino F, Ponzoni M, Righetti PG.

J Chromatogr B Analyt Technol Biomed Life Sci. 2004 Sep 5;808(2):279-86.

PMID:
15261822
30.

Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.

Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, Longhi R, Allen TM, Corti A, Ponzoni M.

Cancer Res. 2003 Nov 1;63(21):7400-9.

31.

Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.

Pastorino F, Brignole C, Marimpietri D, Pagnan G, Morando A, Ribatti D, Semple SC, Gambini C, Allen TM, Ponzoni M.

Clin Cancer Res. 2003 Oct 1;9(12):4595-605.

32.

Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment.

Brignole C, Pagnan G, Marimpietri D, Cosimo E, Allen TM, Ponzoni M, Pastorino F.

Cancer Lett. 2003 Jul 18;197(1-2):231-5. Review.

PMID:
12880987
33.

Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse.

Raffaghello L, Marimpietri D, Pagnan G, Pastorino F, Cosimo E, Brignole C, Ponzoni M, Montaldo PG.

Cancer Lett. 2003 Jul 18;197(1-2):205-9. Review.

PMID:
12880983
34.

Development of Fab' fragments of anti-GD(2) immunoliposomes entrapping doxorubicin for experimental therapy of human neuroblastoma.

Brignole C, Marimpietri D, Gambini C, Allen TM, Ponzoni M, Pastorino F.

Cancer Lett. 2003 Jul 18;197(1-2):199-204. Review.

PMID:
12880982
35.

Fenretinide as an anti-angiogenic agent in neuroblastoma.

Ribatti D, Raffaghello L, Marimpietri D, Cosimo E, Montaldo PG, Nico B, Vacca A, Ponzoni M.

Cancer Lett. 2003 Jul 18;197(1-2):181-4. Review.

PMID:
12880979
36.

Immunoliposomal fenretinide: a novel antitumoral drug for human neuroblastoma.

Raffaghello L, Pagnan G, Pastorino F, Cosimo E, Brignole C, Marimpietri D, Bogenmann E, Ponzoni M, Montaldo PG.

Cancer Lett. 2003 Jul 18;197(1-2):151-5. Review.

PMID:
12880975
37.

In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma.

Raffaghello L, Pagnan G, Pastorino F, Cosimo E, Brignole C, Marimpietri D, Montaldo PG, Gambini C, Allen TM, Bogenmann E, Ponzoni M.

Int J Cancer. 2003 May 1;104(5):559-67.

38.

Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.

Pastorino F, Brignole C, Marimpietri D, Sapra P, Moase EH, Allen TM, Ponzoni M.

Cancer Res. 2003 Jan 1;63(1):86-92.

39.

Inhibition of neuroblastoma-induced angiogenesis by fenretinide.

Ribatti D, Alessandri G, Baronio M, Raffaghello L, Cosimo E, Marimpietri D, Montaldo PG, De Falco G, Caruso A, Vacca A, Ponzoni M.

Int J Cancer. 2001 Nov 1;94(3):314-21.

40.

Sodium butyrate modulates cell cycle-related proteins in HT29 human colonic adenocarcinoma cells.

Coradini D, Pellizzaro C, Marimpietri D, Abolafio G, Daidone MG.

Cell Prolif. 2000 Jun;33(3):139-46.

PMID:
10959623
41.

Tissue transglutaminase is a caspase substrate during apoptosis. Cleavage causes loss of transamidating function and is a biochemical marker of caspase 3 activation.

Fabbi M, Marimpietri D, Martini S, Brancolini C, Amoresano A, Scaloni A, Bargellesi A, Cosulich E.

Cell Death Differ. 1999 Oct;6(10):992-1001.

42.

Biochemical characterization and membrane expression of an antigen shared by activated and neoplastic cells of neuroectodermal origin.

Baldissarro I, Marroni P, Smilovich D, Capra MC, Marimpietri D, Montalti S, Severi AB, Grossi CE, Cosulich ME.

J Neuroimmunol. 1995 Mar;57(1-2):17-26.

PMID:
7706433

Supplemental Content

Loading ...
Support Center